Welcome to our dedicated page for iHuman SEC filings (Ticker: IH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iHuman Inc. filings document its foreign-issuer reporting as a China-based provider of tech-powered intellectual development products whose American depositary shares represent Class A ordinary shares. Current reports on Form 6-K furnish press releases on quarterly and annual results, including revenue, gross profit, operating income, net income, average total MAUs, deferred revenue, and customer advances.
The company’s regulatory record also includes annual Form 20-F reporting and related ADS disclosures. These filings address the company’s product portfolio, subscription and content-driven business model, dividend actions, governance framework, capital structure, and risk disclosures for its apps, interactive content, smart devices, and China-centered operations.
iHuman Inc. filed an initial insider ownership report showing that Chief Strategy Officer Lin Congyu holds 8,000 American Depositary Shares (ADS) of the company. A footnote explains that each ADS represents five Class A ordinary shares, clarifying the economic interest tied to these holdings.
iHuman Inc. filed an initial Form 3 for Li Teng, who serves as Co-Chief Executive Officer. This filing establishes Li Teng’s status as a reporting insider of the company. The data provided show no reported purchases, sales, or other equity transactions in this filing.
iHuman Inc. reported unaudited first quarter 2026 results showing lower revenue and profit but a small net gain. Revenue was RMB182.5 million (US$26.5 million), down from RMB210.4 million a year earlier, as China’s declining newborn population and cautious consumer spending weighed on demand. Average monthly active users were 23.62 million versus 26.51 million.
Gross profit fell to RMB122.0 million with a 66.8% gross margin, slightly below 68.3% last year. Total operating expenses rose 8.1% to RMB132.1 million, driven mainly by higher sales and marketing spending, leading to an operating loss of RMB10.1 million. Thanks to higher other income, the company still recorded net income of RMB4.5 million, or RMB0.09 per ADS.
iHuman ended the quarter with cash, cash equivalents and short-term investments of RMB1,099.9 million and deferred revenue and customer advances of RMB208.1 million. It is integrating the acquisitions of All Knowledge and Perfect Lingo, with upfront consideration of RMB67.0 million and RMB27.0 million plus potential earn-outs, to broaden its AI-powered learning ecosystem.
iHuman Inc. is acquiring the businesses and assets behind two AI-powered learning apps, All Knowledge and Perfect Lingo, for aggregate consideration of RMB94.0 million, subject to possible price adjustments and earn-out payments. The deal brings humanities-focused and English vocabulary/AI learning products that complement iHuman’s existing education ecosystem.
The acquisition prices may be reduced to RMB51.0 million for All Knowledge and RMB21.0 million for Perfect Lingo if specified material adverse events occur, while additional earn-outs of up to RMB29.0 million and RMB12.0 million are available if financial targets over the next three years are met. iHuman engaged a Big Four firm for independent valuation, and its board and audit committee approved the related party transactions. Upon closing, Teng Li from All Knowledge and Perfect Lingo will become Co-CEO, and Congyu Lin will join as Chief Strategy Officer, strengthening management depth and industry expertise.
iHuman Inc., a Cayman Islands holding company whose business in mainland China is conducted mainly through a variable interest entity structure, filed its annual report for the year ended December 31, 2025.
Revenue declined to RMB807.0 million in 2025 from RMB922.2 million in 2024 and RMB1,018.1 million in 2023, reflecting pressure on its tech-powered children’s intellectual development business. Despite lower revenue, net income was RMB95.4 million, only slightly below RMB98.6 million in 2024, supported by reduced operating expenses. Cash and cash equivalents were RMB1,151.1 million as of December 31, 2025, and total shareholders’ equity reached RMB995.2 million.
The company highlights substantial regulatory and structural risks: operations rely on contractual arrangements with a VIE in mainland China, are exposed to evolving education, data and internet rules, and could be affected by future changes under CSRC filing rules, cybersecurity review and the Holding Foreign Companies Accountable Act. It also discloses detailed cash-flow pathways between the Cayman holding company, Hong Kong entities, PRC subsidiaries and the VIE, including dividends of RMB35.3 million in 2024 and RMB39.1 million (US$5.6 million) in 2025 and a special cash dividend of US$0.02 per ordinary share (US$0.10 per ADS) approved in March 2026.
iHuman Inc. reported unaudited fourth quarter and full-year 2025 results showing lower revenue but continued profitability and strong cash reserves. Q4 2025 revenue was RMB190.7 million, down from RMB232.7 million, with net income of RMB15.4 million versus RMB26.5 million a year earlier.
For fiscal 2025, revenue was RMB807.0 million compared with RMB922.2 million in 2024, while net income held relatively steady at RMB95.4 million versus RMB98.6 million. Gross margin remained high at 67.9%, supported by cost controls that reduced operating expenses by 15.4%.
Average total MAUs declined modestly to 24.98 million for the year as China’s newborn population fell, but the company ended 2025 with RMB1,151.1 million in cash, cash equivalents and short-term investments. Reflecting confidence in its position, the board approved a special cash dividend of US$0.10 per ADS, totaling about US$5.1 million.
iHuman Inc. Chief Technology Officer Lu Wenbin has filed an initial Form 3 reporting his beneficial ownership in the company. The filing shows indirect ownership of 8,000,000 Class A ordinary shares of iHuman Inc., held through Hui Yu LWB Holding Ltd. This Form 3 records existing holdings rather than detailing a new purchase or sale.
iHuman Inc. director Wendy W. Hayes filed an initial Form 3 reporting option holdings tied to Class A ordinary shares. She holds options covering 53,000 underlying shares at an exercise price of $0.0500 per share expiring on November 30, 2030, and another grant covering 53,000 underlying shares at the same exercise price expiring on December 15, 2032. The earlier grant vested in three annual tranches from October 8, 2021 to October 8, 2023, while the later grant vests in four equal annual installments after its December 15, 2022 grant date. This filing records existing derivative positions and does not show any new purchases or sales.
iHuman Inc. director and Chief Executive Officer Dai Peng filed an initial ownership report showing indirect holdings of 16,000,000 Class A ordinary shares. These shares are reported as held indirectly through Lei Hong DP Holding Ltd. and the filing does not report any recent share purchases or sales.
iHuman Inc. director Chi Yufeng has filed an initial ownership report showing indirect holdings of 144,000,000 Class B ordinary shares. These shares are held through Academy Management Ltd., reflecting a substantial existing stake rather than a new purchase or sale.